MannKind

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. 

CEO
Michael E. Castagna
CEOMichael E. Castagna
Employees
592
Employees592
Headquarters
Danbury, Connecticut
HeadquartersDanbury, Connecticut
Founded
1991
Founded1991
Employees
592
Employees592

MNKD Key Statistics

Market cap
875.01M
Market cap875.01M
Price-Earnings ratio
151.87
Price-Earnings ratio151.87
Dividend yield
Dividend yield
Average volume
3.30M
Average volume3.30M
High today
$2.85
High today$2.85
Low today
$2.76
Low today$2.76
Open price
$2.78
Open price$2.78
Volume
3.55M
Volume3.55M
52 Week high
$6.51
52 Week high$6.51
52 Week low
$2.23
52 Week low$2.23

Stock Snapshot

With a market cap of 875.01M, MannKind(MNKD) trades at $2.82. The stock has a price-to-earnings ratio of 151.87.

On 2026-04-19, MannKind(MNKD) stock traded between a low of $2.76 and a high of $2.85. Shares are currently priced at $2.82, which is +2.3% above the low and -1.1% below the high.

MannKind(MNKD) shares are trading with a volume of 3.55M, against a daily average of 3.3M.

In the last year, MannKind(MNKD) shares hit a 52-week high of $6.51 and a 52-week low of $2.23.

In the last year, MannKind(MNKD) shares hit a 52-week high of $6.51 and a 52-week low of $2.23.

MNKD News

TipRanks 3d
MannKind’s Inhaled Nintedanib Trial: Early IPF Study Moves Forward

MannKind Corporation (MNKD) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper...

TipRanks 6d
MannKind price target lowered to $8 from $10 at Mizuho

Mizuho lowered the firm’s price target on MannKind (MNKD) to $8 from $10 and keeps an Outperform rating on the shares. The firm adjusted estimates and price tar...

Analyst ratings

89%

of 9 ratings
Buy
88.9%
Hold
11.1%
Sell
0%

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.